MSD

News

Keytruda gets surgery-spanning OK from FDA in early NSCLC

MSD’s Keytruda has become the first immunotherapy in the US that can be used continuously, before and after surgery, in patients with early-stage non-small cell lung cance

News

MSD gives warning to UK ahead of $1.3bn facility work

In 2017, MSD made the decision to open a $1.32 billion, 220,000 sq ft research facility in the heart of London’s ‘knowledge quarter’ around King’s Cross.

News

Scotland first in Europe to back MSD drug for VHL tumours

Scotland has become the first country in Europe to recommend coverage of MSD’s Welireg as a treatment for some people with von Hippel-Lindau disease (VHL), a rare genetic

Oncology

An oncology workforce fit for the future

To continue delivering high-quality and patient-centred care, the future oncology workforce of the NHS needs to be agile, expansive, and diverse.

News

One in five men carries HPV linked to cancer

Researchers have estimated that almost one in three men worldwide is infected with at least one genital human papillomavirus (HPV) strain, and one in five is harbouring st

News

Keytruda backed for 'basket' of new cancers via NHS

The UK's cost-effectiveness agency NICE has recommended MSD's PD-1 inhibitor Keytruda for a series of cancers based on genetic abnormalities known as microsatellite instab

Keytruda gets surgery-spanning OK from FDA in early NSCLC

MSD gives warning to UK ahead of $1.3bn facility work

Scotland first in Europe to back MSD drug for VHL tumours

An oncology workforce fit for the future

One in five men carries HPV linked to cancer

Keytruda backed for 'basket' of new cancers via NHS

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

MSD

Editor's Picks